Passage Bio Reports $46.3M Cash, Q1 2027 Runway, Advances FTD Clinical Trials
PASG sits 84% above its 52-week low of $5.124 on light trading volume (0.3× avg).
Summary
Passage Bio reported its fourth quarter and full year 2025 financial results, highlighting $46.3 million in cash and cash equivalents as of December 31, 2025, with a projected cash runway through the first quarter of 2027. The company also provided significant business updates, including the enrollment of the first three FTD-GRN patients in Cohort 3 and the treatment of the first FTD-C9orf72 patient in Cohort 4 of its upliFT-D clinical study. Additionally, Passage Bio is advancing its preclinical program for Huntington's disease, with a clinical candidate selection expected in 2H 2026. For a micro-cap biotech, the cash runway is a critical indicator of financial health and potential for future dilution, and a runway through Q1 2027 is relatively short. The fact that the company's cash position significantly exceeds its market capitalization suggests the market is heavily discounting its pipeline or anticipating substantial future dilution. Investors will be closely watching for updated interim safety and biomarker data from the upliFT-D study and regulatory feedback on the FTD-GRN registrational trial design, both expected in 1H 2026.
At the time of this announcement, PASG was trading at $9.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.4M. The 52-week trading range was $5.12 to $20.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.